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background:  Acute kidney injury (AKI) with transcatheter aortic valve replacement (TAVR) is associated with increased morbidity and 
mortality. Little is known about the incidence and outcomes of AKI with TAVR in U.S. clinical practice.
methods:  Retrospective analysis of 12,422 TAVR patients in STS/ACC TVT Registry 2012-2013. Pre-TAVR estimated glomerular filtration 
rate (eGFR) was assessed by Chronic Kidney Disease Epidemiological Collaboration (CKD-EPI) method, and categorized by stage of CKD 
using National Kidney Foundation guidelines. Incidence and severity of AKI further was delineated by stages by Kidney Improving Global 
Outcomes Workgroup (KDOQI) methodology. Pre-procedure (pre-T), intra-procedure (intra-T), and post-procedure (post-T) variables and 
adverse events were examined in association with AKI.
results:  The incidence of AKI varies with CKD stages (see figure). There is a 4-20 fold increase in hospital mortality for AKI stages I, II, 
and III versus no AKI (2%, 9%, 40%, 2% respectively p<0.001). Median length of stay (LOS) also significantly increased with AKI (7, 9, 17 
days vs. no AKI median LOS of 5 days p< 0.001). Factors associated with AKI included pre-T albumin, intra-T hemodynamics, and post-T 
atrial fib (p<0.001). 
Conclusion:  AKI with TAVR is associated with mortality and prolonged LOS. Strategies to reduce the risk of AKI are needed which may 
improve patient outcomes, and the risk of AKI may inform clinical decision making for TAVR.
 
